羚锐制药上半年净利4.74亿元，同比增长14.85%

Core Viewpoint - Lingrui Pharmaceutical (600285) reported a revenue of 2.099 billion yuan for the first half of 2025, reflecting a year-on-year growth of 10.14%, and a net profit attributable to shareholders of 474 million yuan, up 14.85% year-on-year [1] Financial Performance - The company achieved a revenue of 2.099 billion yuan in the first half of 2025, marking a 10.14% increase compared to the previous year [1] - The net profit attributable to shareholders reached 474 million yuan, representing a 14.85% year-on-year growth [1] Strategic Developments - During the reporting period, the company completed the acquisition of 90% equity in Yingu Pharmaceutical, enhancing its comprehensive layout in the external preparation field [1] - Following the consolidation of Yingu Pharmaceutical into its financial statements, the subsidiary generated a revenue of 98.77 million yuan and a net profit of 13.226 million yuan [1]